Deutsche Bank Adjusts 10x Genomics Price Target to $23 From $17, Maintains Hold Rating

FierceBiotechFederal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months

Endpoints NewsAfter 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion

BioPharma DiveRegenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

Endpoints NewsMapLight to discuss autism drug's future with FDA after Phase 2 miss

BioPharma DiveSanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

Endpoints NewsLilly allies with BioArctic; Antengene and Insilico sign deals

FierceBiotechIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy

BioWorldBiggest gainers and losers for June 15-19, 2026

BioWorldHoliday notice

Endpoints NewsMerck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

FierceBiotechMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

PharmaVoicePfizer CFO departs for consumer goods sector